




RealRate

PHARMACEUTICAL 2021

Sarepta Therapeutics Inc.
Rank 151 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai

The relative strengths and weaknesses of Sarepta Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sarepta Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 92% points. The greatest weakness of Sarepta Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 29% points.

The company's Economic Capital Ratio, given in the ranking table, is -54%, being 300% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	2,485,196
Cost of Goods Sold	0
Intangible Assets	13,628
Liabilities, Current	416,026
Liabilities, Non-Current	763,640
Other Assets	295,464
Other Compr. Net Income	-47
Other Expenses	65,107
Other Liabilities	1,043,293
Other Net Income	11,098
Property and Equipment	190,430
Research and Development	722,343
Revenues	540,099
Selling, General and Administrative Expense	317,875

Output Variable	Value in 1000 USD
Assets	2,984,718
Liabilities	2,222,959
Expenses	1,105,325
Stockholders Equity	761,759
Net Income	-554,128
Comprehensive Net Income	-554,152
Economic Capital Ratio	-54%